Vafidemstat Therapy for ASD Core Symptoms Without Sedation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no FDA-approved treatments that effectively address the core features of autism spectrum disorder (ASD) and current therapies exhibit significant side effects such as sedation and weight gain.

Innovation Solution

Vafidemstat, or a pharmaceutically acceptable salt or solvate thereof, is administered to treat ASD, targeting core features and non-aggressive symptoms, reducing aggression and agitation without sedative effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current approved therapies are used to treat ASD, then irritability associated with ASD is treated, but side effects occur including sedation and weight gain

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by switching from conventional therapy mechanisms to a histone demethylase inhibitor mechanism, fundamentally changing the pharmacological parameter of action to achieve treatment effectiveness without the sedative and weight gain side effects characteristic of current therapies

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent substitutes the mechanical system of conventional ASD therapies with a novel biochemical mechanism involving histone demethylase inhibition, replacing existing treatment paradigms with a fundamentally different approach that targets epigenetic modifications rather than conventional neurotransmitter systems

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If no FDA-approved treatments address core features of ASD, then core features remain untreated, but current therapies only address irritability

Engineering Contradiction:

Improvetreatment coverageVSAvoidcore feature treatment

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies universality by developing a single therapeutic agent that addresses multiple aspects of ASD core features including social communication deficits, repetitive behaviors, and restricted interests, rather than treating only irritability as current therapies do

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP4717313A2Vafidemstat for use in treating autism spectrum disorder

Publication Date: 2026.04.01 ORYZON GENOMICS SA

Figure 1
Figure 2
Figure 3

AI summary

Provided herein is vafidemstat for use in a method of treating autism spectrum disorder.